These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21060029)

  • 1. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.
    Korn EL; Freidlin B; Mooney M; Abrams JS
    J Clin Oncol; 2010 Dec; 28(35):5197-201. PubMed ID: 21060029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
    Schroen AT; Petroni GR; Wang H; Thielen MJ; Sargent D; Benedetti JK; Cronin WM; Wickerham DL; Wang XF; Gray R; Cohn WF; Slingluff CL; Djulbegovic B
    Clin Trials; 2011 Oct; 8(5):591-600. PubMed ID: 21878447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
    Cheng SK; Dietrich MS; Dilts DM
    Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials.
    Cheng SK; Dietrich MS; Dilts DM
    Clin Cancer Res; 2011 Apr; 17(7):1947-55. PubMed ID: 21447723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials.
    Baquet CR; Ellison GL; Mishra SI
    J Clin Oncol; 2008 Jul; 26(20):3380-6. PubMed ID: 18612153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement.
    Tang C; Sherman SI; Price M; Weng J; Davis SE; Hong DS; Yao JC; Buzdar A; Wilding G; Lee JJ
    Clin Cancer Res; 2017 Mar; 23(6):1414-1421. PubMed ID: 28275168
    [No Abstract]   [Full Text] [Related]  

  • 7. Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.
    Bennette CS; Ramsey SD; McDermott CL; Carlson JJ; Basu A; Veenstra DL
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26714555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups.
    Schroen AT; Petroni GR; Wang H; Thielen MJ; Gray R; Benedetti J; Wang XF; Sargent DJ; Wickerham DL; Cronin W; Djulbegovic B; Slingluff CL
    Clin Cancer Res; 2012 Jan; 18(1):256-62. PubMed ID: 21976533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Maryland cancer patient participation in National Cancer Institute-supported cancer treatment clinical trials.
    Baquet CR; Ellison GL; Mishra SI
    J Health Care Poor Underserved; 2009 May; 20(2 Suppl):120-34. PubMed ID: 19711497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual.
    Massett HA; Mishkin G; Rubinstein L; Ivy SP; Denicoff A; Godwin E; DiPiazza K; Bolognese J; Zwiebel JA; Abrams JS
    Clin Cancer Res; 2016 Nov; 22(22):5408-5416. PubMed ID: 27401246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.
    Lyss AP; Lilenbaum RC
    Clin Lung Cancer; 2009 Nov; 10(6):410-3. PubMed ID: 19900858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
    Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
    Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated clinical trials.
    Peterson JS; Plana D; Bitterman DS; Johnson SB; Aerts HJWL; Kann BH
    Cancer Med; 2023 Feb; 12(4):4715-4724. PubMed ID: 36398619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III clinical trial development: a process of chutes and ladders.
    Dilts DM; Cheng SK; Crites JS; Sandler AB; Doroshow JH
    Clin Cancer Res; 2010 Nov; 16(22):5381-9. PubMed ID: 21062928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights From Building a New National Cancer Institute Community Oncology Research Program Site.
    Saphner T; Thompson MA; Planton S; Singh M; Glandt N; Robinson L; DeBartolo J
    WMJ; 2016 Aug; 115(4):191-5. PubMed ID: 29099156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Speed of Accrual Into Phase III Oncology Trials: A Comparison Across Geographic Locations.
    Ruther NR; Mathiason MA; Wee SK; Emmel AE; Go RS
    Am J Clin Oncol; 2015 Dec; 38(6):575-82. PubMed ID: 24517955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.
    Sateren WB; Trimble EL; Abrams J; Brawley O; Breen N; Ford L; McCabe M; Kaplan R; Smith M; Ungerleider R; Christian MC
    J Clin Oncol; 2002 Apr; 20(8):2109-17. PubMed ID: 11956272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enrollment of adolescent and young adult patients newly diagnosed with cancer in NCI CTEP-sponsored clinical trials before and after launch of the NCI National Clinical Trials Network.
    Sankaran H; Finnigan SR; McShane LM; Best AF; Seibel NL
    Cancer; 2022 Nov; 128(21):3843-3849. PubMed ID: 36089859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment.
    Zaren HA; Nair S; Go RS; Enos RA; Lanier KS; Thompson MA; Zhao J; Fleming DL; Leighton JC; Gribbin TE; Bryant DM; Carrigan A; Corpening JC; Csapo KA; Dimond EP; Ellison C; Gonzalez MM; Harr JL; Wilkinson K; Denicoff AM
    J Oncol Pract; 2013 Mar; 9(2):e55-61. PubMed ID: 23814525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
    Abrams JS; Mooney MM; Zwiebel JA; Korn EL; Friedman SH; Finnigan SR; Schettino PR; Denicoff AM; Kruhm MG; Montello M; Misra RR; Ansher SS; DiPiazza KJ; Souhan EM; Wickerham DL; Giantonio BJ; O'Donnell RT; Sullivan DM; Soto NI; Fleming GF; Prindiville SA; Petryshyn RA; Hautala JA; Grad O; Zuckerman BL; Meyer RM; Yao JC; Baker LA; Buckner JC; Hortobagyi GN; Doroshow JH
    J Natl Cancer Inst; 2013 Jul; 105(13):954-9. PubMed ID: 23776198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.